or Try an Advanced Search...

    Transgene Sa Stocks List

    Symbol Grade Name % Change
    REPL B Replimune Group, Inc. 1.19
    GNLX C Genelux Corporation -0.31
    TCON F TRACON Pharmaceuticals, Inc. -2.91
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Medicine Biopharmaceutical Clinical Medicine Experimental Cancer Treatments Immunotherapy Oncolytic Virus Virotherapy Age Related Macular Degeneration Akseli Hemminki Biotechnology Blastoma Breast Cancer Cancer Treatment Carcinoma Clinical Development Clinical Trial Colorectal Cancer Drugs Fibrotic Disease

    Related ETFs - A few ETFs which own one or more of the above listed Transgene Sa stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 2.87
    BBC B Virtus LifeSci Biotech Clinical Trials ETF 1.0
    MEDX D Horizon Kinetics Medical ETF 0.99
    PTH D Invesco DWA Healthcare Momentum ETF 0.79
    SBIO B ALPS Medical Breakthroughs ETF 0.53
    View all Transgene Sa ETFs...
    Compare ETFs
    Compare CNCR to BBC Compare CNCR to MEDX Compare MEDX to SBIO

        Transgene Sa Stocks Recent News

        Date Stock Title
        Oct 31 GNLX Genelux: H2 2025 PRROC Data Is A Major Inflection Point
        Oct 31 GNLX Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well
        Oct 30 REPL Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
        Oct 29 GNLX Genelux started at buy by Guggenheim ahead of Olvi-vec data
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Medicine Biopharmaceutical Clinical Medicine Experimental Cancer Treatments Immunotherapy Oncolytic Virus Virotherapy Age Related Macular Degeneration Akseli Hemminki Biotechnology Blastoma Breast Cancer Cancer Treatment Carcinoma Clinical Development Clinical Trial Colorectal Cancer Drugs Fibrotic Disease
        Transgene Sa

        Transgene SA is a French biotechnology company that specializes in the development of therapeutic vaccines and immunotherapies for the treatment of cancer and infectious diseases. The company has developed a number of innovative technologies, including its proprietary Transgene Expression System (TES), which is used to create and deliver therapeutic proteins to target cells. Transgene SA has also developed a number of therapeutic vaccines and immunotherapies, including TG4010, which is currently in clinical trials for the treatment of non-small cell lung cancer.

        Browse All Tags